Corcept Therapeutics (NasdaqCM:CORT) Reports Positive Phase 3 Results Despite 8% Share Price Dip

By Yahoo! Finance   |   5 days ago
Corcept Therapeutics (NasdaqCM:CORT) Reports Positive Phase 3 Results Despite 8% Share Price Dip

Corcept Therapeutics achieved positive results in the ROSELLA trial for ovarian cancer treatment, leading to an 8% increase in share price despite market challenges. With successful clinical trials and financial growth, Corcept stands out in the pharmaceutical industry.

Read More

Did you find this insightful?